Compare MTB & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTB | RMD |
|---|---|---|
| Founded | 1856 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | MTB | RMD |
|---|---|---|
| Price | $207.48 | $244.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 13 |
| Target Price | $216.08 | ★ $289.09 |
| AVG Volume (30 Days) | ★ 990.2K | 970.0K |
| Earning Date | 01-16-2026 | 01-29-2026 |
| Dividend Yield | ★ 2.91% | 0.98% |
| EPS Growth | 19.77 | ★ 29.59 |
| EPS | ★ 16.19 | 9.77 |
| Revenue | ★ $9,080,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | $12.85 | $9.85 |
| Revenue Next Year | $3.67 | $7.36 |
| P/E Ratio | ★ $12.75 | $25.03 |
| Revenue Growth | 6.84 | ★ 9.36 |
| 52 Week Low | $150.75 | $199.92 |
| 52 Week High | $208.26 | $293.81 |
| Indicator | MTB | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 69.90 | 41.85 |
| Support Level | $202.73 | $241.66 |
| Resistance Level | $208.26 | $247.45 |
| Average True Range (ATR) | 3.42 | 5.02 |
| MACD | 0.32 | -0.37 |
| Stochastic Oscillator | 92.88 | 14.57 |
M&T Bank is a US regional bank with roughly $210 billion in assets as of June 30, 2025. Headquartered in Buffalo, New York, the bank's footprint is mostly concentrated in New England and the US Mid-Atlantic. M&T Bank boasts a community banking approach, and boasts over 900 branches in 13 states and Washington, D.C. Apart from retail and commercial banking, M&T Bank also has wealth management operations through Wilmington Trust and a partnership with LPL Financial, and a corporate trust businesses.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.